A comprehensive approach to identifying repurposed drugs to treat SCN8A epilepsy

Many previous studies of drug repurposing have relied on literature review followed by evaluation of a limited number of candidate compounds. Here, we demonstrate the feasibility of a more comprehensive approach using high‐throughput screening to identify inhibitors of a gain‐of‐function mutation in the SCN8A gene associated with severe pediatric epilepsy.

• Publication year

  2018

• Venue

  Epilepsia

• Publication date

  2018-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/epi.14037PMID 29574705
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Development of a Rapid Throughput Assay for Identification of hNav1.7 Antagonist Using Unique Efficacious Sodium Channel Agonist, Antillatoxin

  2016cited by this paper
• SCN8A encephalopathy: Research progress and prospects

  2016cited by this paper
• Validation and Optimization of Novel High-Throughput Assays for Human Epithelial Sodium Channels

  2015cited by this paper
• Aeroplysinin-1, a Sponge-Derived Multi-Targeted Bioactive Marine Drug

  2015cited by this paper
• Pathogenic mechanism of recurrent mutations of SCN8A in epileptic encephalopathy

  2015cited by this paper
• A roadmap for precision medicine in the epilepsies.

  2015cited by this paper
• Targeted resequencing in epileptic encephalopathies identifies de novo mutations in CHD2 and SYNGAP1

  2013cited by this paper
• Rare diseases and orphan drugs

  2012cited by this paper
• Molecular determinants of local anesthetic action of beta-blocking drugs: Implications for therapeutic management of long QT syndrome variant 3.

  2010cited by this paper
• Actions of veratridine on tetrodotoxin‐sensitive voltage‐gated Na+ currents, NaV1.6, in murine vas deferens myocytes

  2009cited by this paper
• Distinct contributions of Nav1.6 and Nav1.2 in action potential initiation and backpropagation

  2009cited by this paper
• ProTx-II, a Selective Inhibitor of NaV1.7 Sodium Channels, Blocks Action Potential Propagation in Nociceptors

  2008cited by this paper
• Characterization of voltage-gated sodium-channel blockers by electrical stimulation and fluorescence detection of membrane potential

  2006cited by this paper
• New positron emission tomography tracer [11C]carvedilol reveals P‐glycoprotein modulation kinetics

  2005cited by this paper
• Electrophysiological properties of two axonal sodium channels, Nav1.2 and Nav1.6, expressed in mouse spinal sensory neurones

  2005cited by this paper
• The neurobiology of antiepileptic drugs

  2004cited by this paper
• Brain concentrations of tricyclic antidepressants: Single-dose kinetics and relationship to plasma concentrations in chronically dosed rats

  2004cited by this paper
• State‐dependent block of voltage‐gated Na+ channels by amitriptyline via the local anesthetic receptor and its implication for neuropathic pain

  2004cited by this paper
• Steady‐State Pharmacokinetics of Carvedilol and Its Enantiomers in Patients with Congestive Heart Failure

  2000cited by this paper
• Sodium channel Na(v)1.6 is localized at nodes of ranvier, dendrites, and synapses.

  2000cited by this paper
• Functional Analysis of the Mouse Scn8a Sodium Channel

  1998cited by this paper
• Altered subthreshold sodium currents and disrupted firing patterns in Purkinje neurons of Scn8a mutant mice.

  1997cited by this paper
• Interaction of the antiepileptic drug lamotrigine with recombinant rat brain type IIA Na+ channels and with native Na+ channels in rat hippocampal neurones

  1995cited by this paper
• Nilvadipine: profile of a new calcium antagonist. An overview.

  1994cited by this paper
• Nilvadipine as a neuroprotective calcium entry blocker in a rat model of global cerebral ischemia. A comparative study with nicardipine hydrochloride.

  1992cited by this paper
• Blockade of cardiac sodium channels by amitriptyline and diphenylhydantoin. Evidence for two use-dependent binding sites.

  1991cited by this paper
• Diurnal Fluctuations in Free and Total Steady‐State Plasma Levels of Carbamazepine and Correlation with Intermittent Side Effects

  1984cited by this paper
• Carbamazepine and carbamazepine-10, 11-epoxide concentrations in human brain.

  1977cited by this paper
• Amitriptyline plasma levels and therapeutic response

  1976cited by this paper

• Targeted therapies in epilepsies.

  2025cites this paper
• Precision Therapeutics in Lennox–Gastaut Syndrome: Targeting Molecular Pathophysiology in a Developmental and Epileptic Encephalopathy

  2025cites this paper
• Voltage-gated sodium channels in the nervous system: Molecular physiology to therapeutic interventions.

  2025cites this paper
• Current and Emerging Precision Therapies for Developmental and Epileptic Encephalopathies.

  2025cites this paper
• Carvedilol increases seizure resistance in a mouse model of SCN8A-derived epilepsy

  2024cites this paper
• Carvedilol inhibits neuronal hyperexcitability caused by epilepsy‐associated KCNT1 mutations

  2024influential citation
• Steps to Improve Precision Medicine in Epilepsy

  2023cites this paper
• (R,S)-trihexyphenidyl, acting via a muscarinic receptor-independent mechanism, inhibits hippocampal glutamatergic and GABAergic synaptic transmissions: Potential relevance for treatment of organophosphorus intoxication.

  2023cites this paper
• Mechanism of carvedilol induced action potential and calcium alternans

  2022influential citation
• Gene variant effects across sodium channelopathies predict function and guide precision therapy

  2022cites this paper
• KCNQ2 R144 variants cause neurodevelopmental disability with language impairment and autistic features without neonatal seizures through a gain-of-function mechanism

  2022cites this paper
• Precision medicine for genetic epilepsy on the horizon: Recent advances, present challenges, and suggestions for continued progress

  2022cites this paper
• Dissolution mechanism of supported phospholipid bilayer in the presence of amphiphilic drug investigated by neutron reflectometry and quartz crystal microbalance with dissipation monitoring.

  2022cites this paper
• Eugenol inhibits veratridine-induced non-convulsive seizures and wet dog shakes via blockage of sodium and calcium influx in rat cerebrocortical synaptosomes

  2022cites this paper
• Identification of pathological transcription in autosomal dominant polycystic kidney disease epithelia

  2021cites this paper
• Sodium Channelopathies of Skeletal Muscle and Brain.

  2021cites this paper
• SCN1A and Its Related Epileptic Phenotypes

  2021cites this paper
• Rational Small Molecule Treatment for Genetic Epilepsies

  2021cites this paper
• The pharmacological treatment of epilepsy: recent advances and future perspectives

  2021cites this paper
• Efficacy of levetiracetam in STXBP1 encephalopathy with different phenotypic and genetic spectra.

  2021cites this paper
• SCN2A and Its Related Epileptic Phenotypes

  2021cites this paper
• SCN8A and Its Related Epileptic Phenotypes

  2021cites this paper
• Using Xenopus oocytes in neurological disease drug discovery

  2020cites this paper
• Precision medicine and therapies of the future

  2020cites this paper
• Postbiotic-Enabled Targeting of the Host-Microbiota-Pathogen Interface: Hints of Antibiotic Decline?

  2020cites this paper
• Establishing a transcriptome-based drug discovery paradigm for neurodevelopmental disorders

  2020cites this paper
• Effect of carvedilol on atrial excitation-contraction coupling, Ca release and arrhythmogenicity.

  2020cites this paper
• Epilepsy Benchmarks Area II: Prevent Epilepsy and Its Progression

  2020cites this paper
• [EXPRESS] Trigeminal Neuralgia: an overview from pathophysiology to pharmacological treatments.

  2020cites this paper
• A Transcriptome‐Based Drug Discovery Paradigm for Neurodevelopmental Disorders

  2020cites this paper
• Developmental and epileptic encephalopathies: what we do and do not know.

  2020cites this paper
• Phenotypic and genetic spectrum of SCN8A‐related disorders, treatment options, and outcomes

  2019cites this paper
• Drug Development for Rare Paediatric Epilepsies: Current State and Future Directions

  2019cites this paper
• Genetic and clinical features of SCN8A developmental and epileptic encephalopathy.

  2019cites this paper
• Recent advances in treatment of epilepsy-related sodium channelopathies.

  2019cites this paper
• Why we urgently need improved epilepsy therapies for adult patients.

  2019cites this paper
• Novel therapies for epilepsy in the pipeline.

  2019cites this paper
• Identifying mutations in epilepsy genes: Impact on treatment selection.

  2019cites this paper
• Neuronal mechanisms of mutations in SCN8A causing epilepsy or intellectual disability

  2019cites this paper